Nobelpharma said that it has rolled out its Hyftor (sirolimus topical gel) in the US on August 29 for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and children aged six and older. Hyftor, sold…
To read the full story
Related Article
- Hyftor Now Available in EU, UK: Nobelpharma
October 31, 2023
- Nobelpharma Bags UK Approval for Hyftor
September 5, 2023
- Nobelpharma Gets EU Nod for Hyftor
May 30, 2023
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





